ArticleScientific reports2025
Novel m
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- mBiology direct · 2026Review
- m5C and m6A cooperatively stabilize EPHB4 to drive lymphatic metastasis in gastric cancer.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lymphatic metastasis is a critical determinant of poor prognosis in gastric cancer (GC), yet the underlying regulatory mechanisms remain incompletely understood. While kinesin family member 11 (KIF11) is known to promote lymphangiogenesis, its upstream post-transcriptional regulation in GC has not been elucidated. In this study, we demonstrate for the first time that KIF11 is a direct target of 5-methylcytosine (m5C) RNA modification, which is mediated by the methyltransferase NSUN2 and recognized by the m5C reader YBX1. Mechanistically, NSUN2 deposits m5C marks at specific sites on KIF11 mRNA, particularly at C94413695 and C94413832, which are subsequently recognized by YBX1 to enhance mRNA stability and elevate KIF11 expression. Functionally, upregulated KIF11 promotes lymphangiogenesis by facilitating the Golgi localization and secretion of pro-lymphangiogenic proteins, thereby accelerating lymph node metastasis in GC. These findings uncover a previously unrecognized NSUN2/YBX1–KIF11 regulatory axis and establish m5C-dependent post-transcriptional regulation as a key mechanism linking KIF11 upregulation to lymphangiogenesis and metastatic progression in GC. This study provides novel mechanistic insights and identified potential therapeutic targets for the treatment of metastatic GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.